文献速递神经肿瘤

贝伐珠单抗对NF2相关神经鞘瘤病中非靶颅内脑膜瘤与非前庭神经鞘瘤的影响:NF104研究

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
PubMed 文献 · J Neurooncol · 2025-05-28

本研究回顾性分析NF104试验中22例NF2相关神经鞘瘤病伴进展性前庭神经鞘瘤患者,前瞻性接受贝伐珠单抗治疗两年,评估非靶颅内非前庭神经鞘瘤(NVS)和脑膜瘤的肿瘤体积变化。最佳缓解分析显示脑膜瘤影像学缓解率13%(5/40),NVS为42%(5/12);脑膜瘤进展率55%(22/40),NVS为8%(1/12)。作者认为贝伐珠单抗对NVS活性优于脑膜瘤,其潜在生物学差异需进一步研究。

要点

  • 贝伐珠单抗治疗两年,脑膜瘤影像学缓解率13%(5/40),NVS为42%(5/12)。
  • 脑膜瘤进展率55%(22/40),NVS为8%(1/12)。
  • 脑膜瘤中位进展时间15个月,NVS未达到。

核心结论

  • 贝伐珠单抗对颅内NVS的活性优于脑膜瘤,表现为更有利的缓解率、缓解持久性和进展率。
  • 脑膜瘤与神经鞘瘤对贝伐珠单抗差异反应的潜在生物学差异需进一步研究。

研究设计与样本

  • 回顾性分析NF104试验(NCT01767792)中22例NF2相关神经鞘瘤病伴进展性前庭神经鞘瘤患者,前瞻性接受贝伐珠单抗治疗两年,评估非靶颅内NVS和脑膜瘤的肿瘤体积。
  • 影像学缓解(RR)定义为肿瘤体积较基线减少≥20%,进展(PD)定义为增加≥20%,其他为疾病稳定。

主要发现

  • 共评估8例患者的40个脑膜瘤和6例患者的12个NVS。
  • 最佳缓解分析:脑膜瘤RR为13%(5/40),NVS为42%(5/12)。
  • 按患者分析:脑膜瘤RR为38%(3/8),NVS为67%(4/6)。
  • 两个NVS的缓解在研究期间持续。
  • 治疗两年内,脑膜瘤PD为55%(22/40),NVS为8%(1/12)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bevacizumab treatment is associated with imaging and hearing responses in progressive vestibular schwannoma (VS) caused by NF2-related schwannomatosis (NF2-SWN). However, its effect on co-existing intracranial non-vestibular schwannomas (NVS) and meningiomas is unclear. METHODS: We retrospectively analyzed tumor volumes of non-target intracranial NVS and meningiomas in patients with NF2-SWN and progressive VS who were prospectively treated with bevacizumab for two years on the Neurofibromatosis Clinical Trials Consortium (NFCTC) trial NF104 (NCT01767792). Radiographic response (RR) or progression (PD) were defined as ≥ 20% decrease or ≥ 20% increase in tumor volume compared to baseline, respectively. All other responses were defined as stable disease. RESULTS: A total of 40 meningiomas in eight patients and 12 NVS in six patients were evaluated across 22 enrolled trial participants. On best response analysis, RR occurred in 13% (5/40) of meningiomas and in 42% (5/12) of NVS. On a per-patient basis, RR for meningioma occurred in 38% (3/8) of patients and for NVS in 67% (4/6) of patients. RR in two NVS were durable throughout the study period. During two years of treatment, PD occurred in 55% (22/40) of meningiomas and in 8% (1/12) of NVS. Median time to tumor progression was 15 months for meningiomas and was not reached for NVS. CONCLUSIONS: We observed greater activity of bevacizumab against intracranial NVS compared to meningioma, evidenced by more favorable RR rates, durability of response, and rates of PD. Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Nakhate V, Ly I, Muzikansky A, et al. Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025. PMID: 40434540. doi:10.1007/s11060-025-05020-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。